Business
BioNxt Solutions Announces Revocation of Management Cease Trade Order
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), is pleased to announce that effective immediately, the British Columbia Securities Commission has revoked the ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), is pleased to announce that effective immediately, the British Columbia Securities Commission has revoked the temporary management cease trade order ("MCTO") it had previously granted to the Company on May 1, 2025 under National Policy 12-203 Management Cease Trade Orders, as the Company successfully completed the filing of its annual audited financial statements, management's discussion and analysis, and related certifications for the year ended December 31, 2024 (collectively, the "Annual Filings") on June 26, 2025.","length":704,"tagName":"p"},{"type":"text","content":"The revocation of the MCTO means members of management are no longer prevented from trading the Company's securities. All of the Annual Filings are available under the Company's profile on SEDAR+ at www.sedarplus.ca.","length":224,"tagName":"p"},{"type":"text","content":"About BioNxt Solutions Inc.BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.","length":434,"tagName":"p"},{"type":"text","content":"With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.","length":316,"tagName":"p"},{"type":"text","content":"BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.","length":176,"tagName":"p"},{"type":"text","content":"Investor Relations & Media ContactHugh Rogers, Co‐Founder, CEO and DirectorEmail: [email protected]: +1 778.598.2698","length":140,"tagName":"p"},{"type":"text","content":"Web: www.bionxt.comLinkedIn: https://www.lin...